LVM Capital Management Ltd. MI raised its position in shares of Abbott Laboratories (NYSE:ABT – Get Rating) by 0.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 29,011 shares of the healthcare product maker’s stock after purchasing an additional 226 shares during the quarter. LVM Capital Management Ltd. MI’s holdings in Abbott Laboratories were worth $3,434,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in ABT. New World Advisors LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $477,000. Dark Forest Capital Management LP acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $146,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $103,000. Captrust Financial Advisors grew its position in shares of Abbott Laboratories by 11.9% during the 3rd quarter. Captrust Financial Advisors now owns 275,563 shares of the healthcare product maker’s stock worth $32,552,000 after buying an additional 29,240 shares during the period. Finally, Schonfeld Strategic Advisors LLC grew its position in shares of Abbott Laboratories by 5.6% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 84,874 shares of the healthcare product maker’s stock worth $10,026,000 after buying an additional 4,520 shares during the period. 73.46% of the stock is owned by institutional investors.
In related news, Director Daniel J. Starks sold 50,000 shares of the business’s stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $113.22, for a total value of $5,661,000.00. Following the sale, the director now directly owns 6,973,500 shares in the company, valued at approximately $789,539,670. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Randel William Woodgrift sold 24,000 shares of the business’s stock in a transaction dated Wednesday, May 4th. The shares were sold at an average price of $113.00, for a total value of $2,712,000.00. Following the completion of the sale, the senior vice president now owns 47,854 shares in the company, valued at $5,407,502. The disclosure for this sale can be found here. Insiders own 0.52% of the company’s stock.
NYSE ABT opened at $105.44 on Thursday. The stock has a market capitalization of $184.62 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 3.77 and a beta of 0.73. Abbott Laboratories has a one year low of $101.24 and a one year high of $142.60. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.40. The business’s fifty day moving average is $112.94 and its 200-day moving average is $121.64.
Abbott Laboratories (NYSE:ABT – Get Rating) last released its earnings results on Wednesday, April 20th. The healthcare product maker reported $1.73 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.26. The company had revenue of $11.90 billion for the quarter, compared to analysts’ expectations of $11 billion. Abbott Laboratories had a return on equity of 28.72% and a net margin of 17.35%. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.32 EPS. Research analysts expect that Abbott Laboratories will post 4.84 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.78%. The ex-dividend date of this dividend is Thursday, July 14th. Abbott Laboratories’s payout ratio is 43.62%.
About Abbott Laboratories (Get Rating)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
- Get a free copy of the StockNews.com research report on Abbott Laboratories (ABT)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.